{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "The Alfred Hospital, Melbourne, VIC, Australia",
    "University of Miami, Sylvester Cancer Center, Miami, FL, USA",
    "Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA",
    "7START San Antonio, San Antonio, TX, USA",
    "1Sarah Cannon Research Institute, Nashville, TN, USA",
    "9 START Midwest, Grand Rapids, Michigan, USA",
    "11Southern Oncology Clinical Research Unit, Bedford Park, SA, Australia",
    "Peninsula and South East Oncology, Frankston, VIC, Australia",
    "2Department of Medical Oncology, Monash Health, Clayton, VIC, Australia",
    "Austin Health, Heidelberg, VIC, Australia",
    "15Aulos Bioscience, Larkspur, CA, USA",
    "16Biolojic Design, Rehovot, Israel",
    "Southside Cancer Care, Miranda, NSW, Australia",
    "Carolina BioOncology Institute, PLLC, Huntersville, NC, USA",
    "Minnesota Oncology and Hematology, Minneapolis, MN, USA",
    "Texas Oncology, Austin, TX, USA",
    "Biolojic Design Inc, Cambridge, MA, USA",
    "Aulos Bioscience, San Francisco, CA, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 20,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Andrew Haydon"
    },
    {
      "affs": [
        1
      ],
      "name": "Jose Lutzky"
    },
    {
      "affs": [
        2
      ],
      "name": "Siwen Hu-Lieskovan"
    },
    {
      "affs": [
        3
      ],
      "name": "Drew Rasco"
    },
    {
      "affs": [
        4
      ],
      "name": "Meredith McKean"
    },
    {
      "affs": [
        5
      ],
      "name": "Nehal Lakhani"
    },
    {
      "affs": [
        6
      ],
      "name": "Ganessan Kichenadasse"
    },
    {
      "affs": [
        7
      ],
      "name": "Vinod Ganju"
    },
    {
      "affs": [
        8
      ],
      "name": "Sophia Frentzas"
    },
    {
      "affs": [
        9
      ],
      "name": "Andrew Weickhardt"
    },
    {
      "affs": [
        10
      ],
      "name": "Aron Knickerbocker"
    },
    {
      "affs": [
        11
      ],
      "name": "Yanay Ofran"
    },
    {
      "affs": [
        10
      ],
      "name": "Jenny Tang"
    },
    {
      "affs": [
        10
      ],
      "name": "Lori Richards"
    },
    {
      "affs": [
        12
      ],
      "name": "Paul de Souza"
    },
    {
      "affs": [
        13
      ],
      "name": "John D Powderly"
    },
    {
      "affs": [
        14
      ],
      "name": "Eric Lander"
    },
    {
      "affs": [
        15
      ],
      "name": "Jeffrey T Yorio"
    },
    {
      "affs": [
        16
      ],
      "name": "Timothy L Wyant"
    },
    {
      "affs": [
        17
      ],
      "name": "James R Vasselli"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3bs2yss0hqsyb.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.0611",
  "fulltext_url": null,
  "id": "3bs2yss0hqsyb",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.0611",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225325719",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_2/A690.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-07",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/3bs2yss0hqsyb.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T14:21:11Z",
      "native_id": "03dad4639f5d4cd1873dcdceec6c436c",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.0611"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study",
  "title_text": "611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:38Z",
  "url": "https://research.draconitic.com/paper/3bs2yss0hqsyb",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}